

# ISMP Canada Safety Bulletin


Volume 25 • Issue 5 • May 29, 2025

## Do Not Use: Dangerous Abbreviations, Symbols, and Dose Designations – 2025 Update

When communicating medication information, the use of certain abbreviations, symbols, and dose designations has been identified as a significant contributing factor to serious and potentially fatal medication incidents. In 2006, ISMP Canada published a list of dangerous abbreviations, symbols, and dose designations to avoid;<sup>1</sup> the list was reaffirmed in 2018.<sup>2</sup> This bulletin describes the development of an updated list reflecting the evolution of communication in different care settings.

### METHODOLOGY

To ensure the updated list remains relevant and effective in reducing medication incidents, key development steps were undertaken, as outlined in Figure 1.



The thumbnail shows a table titled 'DO NOT USE Dangerous Abbreviations, Symbols, and Dose Designations' with columns for 'DO NOT USE', 'Dangerous Abbreviations, Symbols, and Dose Designations', and 'ALWAYS USE'. It lists various abbreviations like 'U', 'QID', 'S', etc., and their corresponding safe alternatives.

### Development of an Updated Draft Do Not Use List

- **Environmental scan of academic and grey literature**
  - This captured similar lists from organizational, provincial, and international sources.<sup>3-7</sup>
- **Medication incident analyses**
  - Extracted reports (n = 12,411)\* from a 5-year period (July 1, 2019, to June 30, 2024)
- **Open consultation with stakeholders, including patients/caregivers and health care providers**

### Validation of the Updated Draft Do Not Use List

- **Review and validation questionnaire sent to stakeholders representing**
  - health care sectors (e.g., hospital, long-term care, community pharmacy)
  - health disciplines (e.g., physician, pharmacist, nurse)
  - patients/caregivers
  - health care leadership

### Finalization of ISMP Canada's Updated Do Not Use List

- **Review and finalization of the list by**
  - medication safety specialists
  - ISMP Canada leadership

**FIGURE 1.** Steps undertaken in the development of the 2025 update of the *Do Not Use: Dangerous Abbreviations, Symbols, and Dose Designations*.

\* The reports were submitted to the Consumer Reporting program, the Individual Practitioner Reporting database, the National Incident Data Repository for Community Pharmacies (NIDR), and the Canadian Institute for Health Information's National System for Incident Reporting (NSIR), all of which are components of the Canadian Medication Incident Reporting and Prevention System (CMIRPS). The analyses, conclusions, opinions, and statements expressed herein are those of ISMP Canada.

The number of incidents in which errors could be attributed, at least in part, to the communication of medication information using French-specific abbreviations, symbols, or dose designations was insufficient to identify French-language items for the list.

## HIGHLIGHTS

The following items have been included in the updated *Do Not Use* list:

- **Fractional representations of frequency or duration (e.g., 2/52 to convey 2 weeks)**

In the 2018 review of the *Do Not Use* list, fractions were described as having some association with harm or the potential for harm.<sup>2</sup> Since that publication, reports of medication incidents involving errors of frequency or duration have identified the use of fractional representations as a key contributing factor.

- **Roman numerals (e.g., ii to convey 2)**

In health care, Roman numerals may be mistaken for letters or other numbers, or may be misinterpreted as a route of administration (e.g., iv [representing 4] may be mistakenly interpreted as IV [representing intravenous]).

- **Latin abbreviations for aural (ear) route of administration (e.g., AS for left ear)**

The abbreviations for the aural route of administration (i.e., AS, AD, and AU for left ear, right ear, and both ears, respectively) may be misinterpreted as indicating administration in the eye (i.e., OS, OD, OU, respectively), or they may be mistaken for each other, resulting in treatment of the wrong ear. Previous versions of the *Do Not Use* list already included Latin abbreviations for administration into the eye.

- **Use of the abbreviation “d” to express days or doses**

The use of “d” could be interpreted to mean days or doses (e.g., the expression “for 7 d” could be interpreted as 7 doses, instead of the intended 7-day treatment), resulting in the incorrect duration of treatment.

## INTENDED USE AND RECOMMENDATIONS

Given the range of health care settings and the diversity of populations served, it is recommended that individual organizations and pharmacies adopt the *Do Not Use: Dangerous Abbreviations, Symbols, and Dose Designations* or adapt it to reflect their local context. This approach aligns with accreditation standards.<sup>8</sup>

The Canadian list is applicable to all health care settings in which communication about medication information takes place.

### RECOMMENDATION:

**Individual health care organizations and pharmacies adopt the 2025 *Do Not Use: Dangerous Abbreviations, Symbols, and Dose Designations* or adapt the list to reflect their local context.**

Specifically, health care organizations and pharmacies are encouraged to do the following:

- **Adopt or adapt the *Do Not Use* list** to assist in maintaining an organization-specific list of dangerous abbreviations, symbols, and dose designations.
- **Continuously improve electronic and/or paper information systems** to reduce or obviate the need to use abbreviations (e.g., computerized prescriber order entry [CPOE], paper order sets).
- **Consider using technical functions within electronic information systems** to flag the use of dangerous abbreviations, symbols, and dose designations, and to inform preventive or corrective action.
- **Raise awareness of the *Do Not Use* list**, emphasizing how various shortened forms can be misinterpreted, thereby causing errors, as well as

the need to be as precise and complete as possible when communicating medication-related information. Communicate to staff the importance of reporting medication incidents potentially associated with dangerous abbreviations, symbols, and dose designations.

- **Periodically review the *Do Not Use* list** to identify any abbreviations, symbols, or dose designations that may warrant inclusion or removal to reflect medication incident analysis findings, changes in practice, upgrades to electronic information systems, and/or updates to formularies.

## CONCLUSION

ISMP Canada updated the *Do Not Use* list through a multi-input process that included an environmental scan, incident analyses, and stakeholder consultations from health care sectors and regions across Canada. The list of dangerous abbreviations, symbols, and dose designations considers reported harm (actual or potential), and the frequency of use and/or misinterpretation when communicating medication-related information. Organizations and health care providers are encouraged to adopt or adapt this evidence-informed list to meet the needs of information users in their own care environments.

## ACKNOWLEDGEMENTS

*ISMP Canada gratefully acknowledges the consumers, health care providers, community pharmacies, and organizations who have reported medication incidents for analysis and shared learning.*

## REFERENCES

1. Eliminate use of dangerous abbreviations, symbols, and dose designations. ISMP Can Saf Bull. 2006 [cited 2025 Feb 3];6(4):1-3. Available from: <https://ismpcanada.ca/wp-content/uploads/ISMPCSB2006-04Abbr.pdf>
2. Reaffirming the “Do Not Use: Dangerous Abbreviations, Symbols and Dose Designations” list. ISMP Can Saf Bull. 2018 [cited 2025 Feb 3];18(4):1-4. Available from: <https://ismpcanada.ca/wp-content/uploads/ISMPCSB2018-05-DoNotUseList.pdf>
3. ISMP list of error-prone abbreviations, symbols, and dose designations. Plymouth Meeting (PA): Institute for Safe Medication Practices; 2024 [cited 2025 Feb 7]. Available from: [https://online.ecri.org/hubfs/ISMP/Resources/ISMP\\_ErrorProneAbbreviation\\_List.pdf](https://online.ecri.org/hubfs/ISMP/Resources/ISMP_ErrorProneAbbreviation_List.pdf)
4. Recommendations for terminology, abbreviations and symbols used in medicines communication. A rapid literature review. Sydney (AU): Australian Commission on Safety and Quality in Health Care; 2023 Jun [cited 2025 Feb 3]. Available from: [https://www.safetyandquality.gov.au/sites/default/files/2023-08/recommendations\\_for\\_terminology\\_abbreviations\\_and\\_symbols\\_used\\_in\\_medicines\\_documentation\\_-\\_a\\_rapid\\_literature\\_review\\_0.pdf](https://www.safetyandquality.gov.au/sites/default/files/2023-08/recommendations_for_terminology_abbreviations_and_symbols_used_in_medicines_documentation_-_a_rapid_literature_review_0.pdf)
5. National medication chart user guide (third edition). Wellington (NZ): Health Quality & Safety Commission; 2021 Jan [cited 2025 Feb 7]. Available from: [https://www.hqsc.govt.nz/assets/Our-work/System-safety/Reducing-harm/Medicines/Publications-resources/NMC\\_user\\_guide\\_update\\_2021.pdf](https://www.hqsc.govt.nz/assets/Our-work/System-safety/Reducing-harm/Medicines/Publications-resources/NMC_user_guide_update_2021.pdf)
6. Cheung S, Hoi S, Fernandes O, Huh J, Kynicos S, Murphy L, Lowe D. Audit on the use of dangerous abbreviations, symbols, and dose designations in paper compared to electronic medication orders: a multicenter study. Ann Pharmacother. 2018;52(4):332-337.
7. Samaranayake NR, Cheung DST, Lam MPS, Cheung TT, Chui WCM, Wong ICK, et al. The effectiveness of a 'Do Not Use' list and perceptions of healthcare professionals on error-prone abbreviations. Int J Clin Pharm. 2014;36(5):1000-6.
8. HSO required organizational practices: 2024 handbook. Ottawa (ON): Health Standards Organization; 2024 May [updated 2024 Jul].



The Canadian Medication Incident Reporting and Prevention System (CMIRPS) is a collaborative pan-Canadian program of Health Canada, the Canadian Institute for Health Information (CIHI), the Institute for Safe Medication Practices Canada (ISMP Canada) and Healthcare Excellence Canada (HEC). The goal of CMIRPS is to reduce and prevent harmful medication incidents in Canada.

Funding support provided by Health Canada. The views expressed herein do not necessarily represent the views of Health Canada.



The Healthcare Insurance Reciprocal of Canada (HIROC) provides support for the bulletin and is a member owned expert provider of professional and general liability coverage and risk management support.



The Institute for Safe Medication Practices Canada (ISMP Canada) is an independent national not-for-profit organization committed to the advancement of medication safety in all healthcare settings. ISMP Canada's mandate includes analyzing medication incidents, making recommendations for the prevention of harmful medication incidents, and facilitating quality improvement initiatives.

## Report Medication Incidents

(Including near misses)

**Online:** [www.ismpcanada.ca/report/](http://www.ismpcanada.ca/report/)

**Phone:** 1-866-544-7672

ISMP Canada strives to ensure confidentiality and security of information received, and respects the wishes of the reporter as to the level of detail to be included in publications.

## Stay Informed

To receive ISMP Canada Safety Bulletins and Newsletters visit:

[www.ismpcanada.ca/safety-bulletins/#footer](http://www.ismpcanada.ca/safety-bulletins/#footer)

This bulletin shares information about safe medication practices, is noncommercial, and is therefore exempt from Canadian anti-spam legislation.

## Contact Us

**Email:** [cmirps@ismpcanada.ca](mailto:cmirps@ismpcanada.ca)

**Phone:** 1-866-544-7672

©2025 Institute for Safe Medication Practices Canada.